Skip to Content

Olanzapine Cipla

Previous name: Olanzapine Neopharma
Active Substance: olanzapine
Common Name: olanzapine
ATC Code: N05AH03
Marketing Authorisation Holder: Cipla (EU) Limited
Active Substance: olanzapine
Status: Withdrawn
Authorisation Date: 2007-11-14
Therapeutic Area: Bipolar Disorder Schizophrenia
Pharmacotherapeutic Group: Psycholeptics

Therapeutic Indication

Adults

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

The marketing authorisation for Olanzapine Cipla has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide